About Quantalife
Quantalife is a Healthcare company based in Pleasanton (United States) founded in 2008, and was acquired by Bio Rad in October 2011. Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. Quantalife has raised $28.71 million across 3 funding rounds from investors including Bio Rad, Paladin Capital and Vital Venture Capital. Its focus areas include Life Sciences, Clinical Genomics, Amplification Based and PCR. Its legal entity is QuantaLife, Inc. Its competitors include NeuMoDx, Kryptos Biotechnologies and Senzo; 3 of its 3 listed competitors have raised funding.
Company details
QuantaLife provides tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. It developed Droplet Digital PCR. Droplet Digital PCR provides an absolute measure of target molecules with unrivaled quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. Now this technology is part of Bio-rad as QuantaLife was acquired by Bio-rad in Oct, 2011.
- Headquarters Pleasanton, United States
- Stage Acquired
- SectorsHealthcare
- Website quantalife.com
- Social LinkedIn X
- Acquired by Bio Rad (Oct 2011)
- Legal Name Quantalife, Inc
Funding Insights of Quantalife
Quantalife has successfully raised a total of $28.71M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $3.56 million completed in July 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.71M
- Total Rounds 3
- Last Round Series B — $3.56M
- First Round $7.96M
(May 2009)
- Investors Count 3
All 3 funding rounds of Quantalife with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2011 | $3.56M | Series B | – | – | – |
| Dec 2010 | $17.2M | Series B | – | Paladin Capital | |
| May 2009 | $7.96M | Series A | – | – | – |
4 investors in total: 4 institutional.
Investors in Quantalife
Quantalife has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Bio Rad, Paladin Capital and Vital Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is invested in multiple sectors by Paladin Capital. | paladincapgroup.com | Washington, Dc, United States | ||
Private investments are made in early and later-stage businesses. | 2017 | vitalvc.com | Washington, DC, USA | |
| merieux-developpement.com | ||||
Portfolio of products and services for life science research and clinical diagnostic markets | 1952 | bio-rad.com | Hercules, United States |
Investor details for Quantalife
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Quantalife
4 dated milestones of Quantalife across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Quantalife is founded.
- Funding First funding round of $8.0M.
- Funding Latest funding round, Series B, of $3.6M.
- Exit Acquired by Bio Rad.
Competitors of Quantalife
Quantalife has 3 listed competitors in our database, 3 of them funded. They include NeuMoDx, Kryptos Biotechnologies and Senzo.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| kryptosbio.com | 2017 | Hayward, United States | $12.7M | Point-of-care molecular diagnostics are enabled by Ultrafast Photonic PCR technology. | ||
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. |
Detailed competitors of Quantalife
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Quantalife (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Quantalife
Quantalife was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Quantalife is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
Quantalife is a funded company, having raised a total of $28.71M across 3 funding rounds to date. The company's 1st funding round was a Series A of $7.96M, raised on May 2009.
QuantaLife provides tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. It developed Droplet Digital PCR. Droplet Digital PCR provides an absolute measure of target molecules with unrivaled quantitative resolution and sensitivity. Applications include copy number variation (CNV), mutation detection, and gene expression analysis. Now this technology is part of Bio-rad as QuantaLife was acquired by Bio-rad in Oct, 2011.
Quantalife's top competitors include NeuMoDx, Kryptos Biotechnologies and Senzo.
Quantalife has 4 investors. Key investors include Bio Rad, Paladin Capital, Vital Venture Capital, and Merieux Developement.
Quantalife operates through Quantalife, Inc.
Yes. Quantalife was acquired by Bio Rad in October 2011.